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Clinical Myocardial Injury Related to Neonatal
AsphyxiaSeveral circulating cardiac biomarkers have gained wide
applications in the field of adult and pediatric cardiology,
and their roles in identifying cardiac diseases in newborn
infants are emerging. Among these biomarkers, B-type
natriuretic peptide (BNP) is one of the most frequently
utilized indicators of myocardial strain. Because BNP is
released into the bloodstream in response to mechanical
stress on the ventricular cardiomyocytes, this biomarker
may provide insight into the extent of cardiac compromise
from various hemodynamic insults in the newborn’s heart.
Many previous studies have demonstrated elevated
circulating BNP levels in newborns with hemodynamically
significant patent ductus arteriosus,1 antenatal stress,2
and persistent pulmonary hypertension.3 Studies about
the role of BNP in the context of neonatal asphyxia,
however, are extremely limited. One previous study by
Zhang et al4 showed that infants with hypoxiceischemic
encephalopathy and myocardial ischemic injury had
elevated NT-proBNP levels compared with healthy infants.
Perhaps one of the difficulties in conducting studies
related to neonatal asphyxia is the limitation in case
numbers, as the incidence of perinatal asphyxia is re-
ported to be only 1/1000 live births in resource-rich
countries.5
In this issue of Pediatrics and Neonatology, a study from
China investigated the clinical utility of NT-proBNP in a
large cohort of patients with neonatal asphyxia.6 Zhu and
Nie6 included 106 patients with neonatal asphyxia within a
1-year study period, including 46 cases with clinical evi-
dence of myocardial injury. Serum levels of NT-proNP were
determined at the age of <3 days and again at the 14th day
after admission. In addition, they enrolled 63 cases
admitted to the hospital because of mild viral illness or
omphalitis at similar age (<3 days) as the control group.
The scarcity of both study and control groups and the
availability of repeated NT-proBNP data constitute the
most unique features of this study. Their result showed thathttp://dx.doi.org/10.1016/j.pedneo.2016.02.001
1875-9572/Copyrightª 2016, Taiwan Pediatric Association. Published by
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the baseline NT-proBNP level was significantly elevated in
clinical evidence of myocardial injury, compared with those
without cardiac injury and the control group. Although
there is a wide range of normal values of NT-proBNP in the
newborn period, the authors provided a cutoff value of
3612.5 pg/mL to distinguish between patients with or
without clinical myocardial injury. At follow up, NT-proBNP
level dropped significantly in those with myocardial injury
at birth, but not in those without myocardial injury and
control cases.
Current diagnosis of myocardial injury in newborns with
neonatal asphyxia relies on several different clinical
criteria. Result from this study provides evidence on the
usefulness of serum NT-proBNP level in aiding the diagnosis
of myocardial injury related to neonatal asphyxia. None-
theless, interpretation of these findings should be under-
taken with caution. In this study cohort, a high proportion
of patients with severe asphyxia had other comorbidities
other than myocardial injury, including patent ductus
arteriosus and respiratory distress syndrome, which might
increase hemodynamic burden on the ventricles and sub-
sequently result in elevated NT-proBNP level. Furthermore,
the definition of mild versus severe asphyxia in this study
was based on the 1-minute Apgar score, rather than the 5-
minute score. Compared with the 1-minute Apgar score,
the 5-minute Apgar score is a more useful index of the
response to resuscitation, and it has been shown to predict
neonatal outcomes.7 As NT-proBNP level had little
discriminative value in terms of the 5-minute score (as the
author mentioned in the Discussion section), the question
about the prognostic significance of baseline NT-proBNP
level remains. Lastly, it is still unknown whether
measuring serum NT-proBNP level can guide therapy and
improve outcomes in patients with neonatal asphyxia and
myocardial injury. Further studies are warranted to address
these issues.Elsevier Taiwan LLC. This is an open access article under the CC BY-
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